Table 6.
Cancer pain management of participants according to their incident pain status.
| Characteristic | Incident paina | All patients | p value | |
|---|---|---|---|---|
| Absent n = 190 (%) | Present n = 181 (%) | Total n = 371 (%) | ||
| Opioid use | ||||
| No regular opioid prescription | 36 (19.0) | 6 (3.3) | 42 (11.3) | <0.001 |
| MEDD, median (interquartile range) | 30 (13.5–60) | 30 (22.5–60) | 30 (20–60) | 0.003 |
| Logn MEDD, mean ± SD | 3.0 ± 1.6 | 3.6 ± 1.0 | 3.3 ± 1.4 | <0.0001 |
|
| ||||
| Adjuvant analgesic use | ||||
| Corticosteroid | 21 (11.1) | 40 (22.1) | 61 (16.4) | 0.004 |
| Benzodiazepine | 45 (23.7) | 42 (23.2) | 87 (23.5) | 0.913 |
| Antiepileptic | 23 (12.1) | 46 (25.4) | 69 (18.6) | 0.001 |
| Antidepressant | 30 (15.8) | 24 (13.3) | 54 (14.6) | 0.490 |
| Bisphosphonate | 2 (1.1) | 9 (5.0) | 11 (3.0) | 0.026 |
| Use of ≥1 adjuvant | 97 (51.1) | 113 (62.4) | 210 (56.6) | 0.027 |
|
| ||||
| Pain Management Index (PMI) | ||||
| PMI negative | 55 (29.0) | 40 (22.1) | 95 (25.6) | 0.131 |
MEDD = total morphine equivalent daily dose in mg, oral. aStudy-defined, based on history and on BPI scores.